In the wake of mounting lawsuits against manufacturers of transvaginal mesh devices implanted in women to treat a litany of internal conditions, the U.S. Food and Drug Administration ("FDA") is now moving to heighten the risk label associated with transvaginal mesh specifically used to treat pelvic organ prolapse ("POP").  The risk label for mesh devices used to treat POP will be heightened from "low" to "intermediate." If the new standard is adopted after a mandatory 90-day public comment period, manufacturers of... Read More

Pelvic Organ Prolapse ("POP"), aka bladder prolapse, and Stress Urinary Incontinence ("SUI") are common conditions in women.  The University of Rochester Medical Center conducted a study of 16,616 women with a uterus and found that 41% have experienced POP.  SUI’s prevalence is said to occur in 30% of women five years after a vaginal delivery, but due to its seemingly embarrassing nature, SUI is underreported and many who suffer from it do not seek treatment.  Dr. Memel Harrison conducted a study through... Read More